Vilfuro-G (vilanterol/fluticasone furoate/glycopyrronium bromide FDC) / Lupin - LARVOL DELTA

Glenmark gets CDSCO Panel nod to study Glycopyrronium, Fluticasone Furoate, Vilanterol Powder for Inhalation (Medical Dialogues) - "In line with the revised Phase IV clinical trial protocol of Glycopyrronium 50 mcg plus Fluticasone Furoate 100 mcg plus Vilanterol 25 mcg Powder for Inhalation, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to Glenmark for conducting the Phase IV clinical trial of the proposed FDC. In addition, the committee recommended that the firm submit the Phase IV clinical trial report to CDSCO for further review by the committee....At the recent SEC meeting for Pulmonary held on 11th March 2025, the expert panel reviewed the proposal along with the revised Phase IV CT protocol."

New P3 trial • Chronic Obstructive Pulmonary Disease

Lupin Launches World’s First Fixed-dose Triple Combination Drug, Vilfuro-G for COPD Management in India (Lupin Pharmaceuticals Press Release) - "Global pharma major Lupin Limited (Lupin) announced that it has launched the world’s first fixed-dose triple combination drug (FDC) under the brand name Vilfuro-G^® for the effective management of chronic obstructive pulmonary disease (COPD) in India."

Launch non-US • Chronic Obstructive Pulmonary Disease